|
|
|
|
Vol. 18, Issue 6, 2322-2335, June 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



*Department of Life Science, and ||Research Center for Biomolecular Nanotechnology, Gwangju Institute of Science and Technology, Gwangju 500-712, Korea;
Department of Pharmacology, Kyungpook National University, Daegu 700-422, Korea;
Digestive Disease Research Institute, Wonkwang University School of Medicine, Iksan, Chonbuk 570-749, Korea; and
Division of Biological Sciences, College of Natural Science, Chonbuk National University, Jeonju, Chonbuk 561-756, Korea
Submitted August 24, 2006;
Revised March 28, 2007;
Accepted April 2, 2007
Monitoring Editor: Yu-li Wang
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
2 integrinmediated leukocyte adhesion, and migration across endothelium. Initial rolling is mediated by selectin/glycosylated ligand interactions. The subsequent arrest and adhesion strengthening of leukocytes on the endothelium is mediated by integrins with an Ig superfamily (IgSF) of adhesion molecules on endothelial cells. Morphological changes of leukocytes then accompany the transmigration of leukocytes through the endothelial cell barrier (Springer, 1994
Over the last few years, leukocyte responses to integrin engagement have been studied extensively, whereas the responses of endothelial cells have received much less attention. However, it has become evident that in addition to enabling leukocytes to adhere to endothelium, adhesion molecules are also involved in the initiation of intracellular signaling systems. In addition, leukocyte migration through endothelium is known to be associated with alterations in the functional state of endothelium, e.g., expression of surface proteins, secretion of cytokines, and increased permeability to macromolecules. These responses are coupled with intracellular modifications including cytoskeletal rearrangement, protein phosphorylation, and calcium influx (Male et al., 1994
).
ICAM-1 is a member of the IgSF of adhesion molecules, which is barely detectable in normal endothelial cells, but its expression is enhanced on endothelial cells in response to inflammatory cytokines such as tumor necrosis factor alpha (TNF-
), IL-1
, and IFN-
(Dustin and Springer, 1988
). Antibodies to ICAM-1 inhibit leukocyte adhesion to endothelial cells, granulocyte migration through endothelium, and mitogen and Ag-induced lymphocyte proliferation (Smith et al., 1988
, 1989
). Crystal structures have been determined for domains 12 (D1D2) and 35 (D3D5) of ICAM-1 (Casasnovas et al., 1998
; Yang et al., 2004
), respectively, and the binding mechanism of ICAM-1 to its receptor, LFA-1, has been characterized in great detail (Jun et al., 2001a
,b
; Shimaoka et al., 2003
).
In addition to the important role of the extracellular domain of ICAM-1, the intracellular domain also plays a pivotal role in leukocyte transendothelial migration (TEM), but has no catalytic activity (Sans et al., 2001
; Greenwood et al., 2003
). After ICAM-1 cross-linking or coculture with leukocytes, endothelial ICAM-1 initiates intracellular calcium flux and cytoskeletal signal transduction events, including activation of Rho GTPase and phosphorylation of cortactin, paxillin, p130cas, and focal-adhesion kinase (Durieu-Trautmann et al., 1994
; Etienne et al., 1998
; Adamson et al., 1999
; Thompson et al., 2002
). Leukocyte TEM is inhibited after the inactivation of endothelial cells' Rho protein function (Adamson et al., 1999
), thereby suggesting a proactive role for ICAM-1 signaling/cytoskeletal interactions in facilitating TEM. In agreement with these lines, the intracellular domain of ICAM-1 can bind to a variety of molecules, such as
-actinin (Carpen et al., 1992
),
-tubulin, GAPDH (Federici et al., 1996
), and ezrin (Heiska et al., 1998
). These proteins all have the potential to perform signaling functions. In addition, several reports have described that the deletion of intracellular domain of ICAM-1 abolishes T-lymphocyte migration (Greenwood et al., 2003
) as well as PMN migration (Sans et al., 2001
).
Despite these extensive studies, however, it is still not clearly delineated whether or not the intracellular domain directly affects the spatial organization and distribution of ICAM-1 on the membrane. Moreover, the linkage between the surface topography of ICAM-1 and its functional consequence in leukocyte TEM has not been determined. To answer these questions, we engineered stable COS-7 cell lines expressing various mutant ICAM-1-GFP proteins whose entire or a part of their intracellular domain was deleted; we then directly visualized them using live time-lapse epifluorescence (EPI) and confocal microscopy. We were able to describe the physical distribution as well as the temporal distribution dynamics of ICAM-1 on live cells existing with or without LFA-1 engagement. This strategy also allowed us to overcome the problem of the multiple adhesion receptors found on endothelial cells.
Recent reports have demonstrated that ICAM-1/LFA-1 or VCAM-1/VLA-4 interactions promote formation of endothelial projections that surround adherent lymphocytes and are enriched in ICAM-1, VCAM-1, ezrin, and actin (Barreiro et al., 2002
; Carman et al., 2003
). High-resolution imaging study has also suggested that this structure may function to facilitate and guide TEM by forming a cuplike traction structure called a "transmigratory cup" that is aligned parallel to the direction of transmigration (Carman and Springer, 2004
). These studies were intriguing and raised the question of what specific site(s) in the intracellular domain is/are responsible for such transmigratory cup formation in the context of leukocyte/endothelial interactions. We found that 507RKIKK511 residues in the NH-terminal third of the intracellular domain are required for ICAM-1 membrane projection in response to binding LFA-1 on leukocytes. Accordingly, cell-permeant peptide comprising RKIKK sequences dramatically reduced leukocyte TEM. Importantly, we also found that 507RKIKK511 is an essential motif for the microvillus presentation of ICAM-1. The present results imply a novel regulatory role for ICAM-1 topography in leukocyte TEM.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Antibodies and Reagents
Antibody to human ICAM-1 (R6.5) was purified from R6.5 hybridoma (ATCC HB-9580), and anti-GFP was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). CBR-LFA1/2 mAb was kindly provided by Dr. T. A. Springer (Center for Blood Research, Boston, MA). R-phycoerythrin (PE) or fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG and Phalloidin-TRITC were purchased from Sigma (St. Louis, MO). Monoclonal anti-ezrin and anti-moesin were acquired from BD Biosciences (San Diego, CA), and Cy5-conjugated anti-mouse IgG was from Molecular Probes (Eugene, OR). Polyclonal anti-phospho ERM (pERM) and anti-ezrin were purchased from Cell Signaling Technology (Beverly, MA). Horseradish peroxidaseconjugated anti-mouse IgG was purchased from Amersham Biosciences. Anti-ICAM-1 (CBR IC1/11) Fab was prepared by papain cleavage using the ImmunoPure Fab Preparation kit (Pierce, Rockford, IL) according to the manufacturer's instructions. Conjugation of anti-ICAM-1 Fab to Cy-3 bisfunctional dyes (Amersham Pharmacia Biotech, Piscataway, NJ) was also performed by the manufacturer's instruction manual. Human TNF-
, SDF-1
, and anti-pECAM-1 antibody were purchased from R&D Systems (Minneapolis, MN). Lipofectamine 2000 reagent was from Invitrogen (Carlsbad, CA). Small interfering RNA (siRNA) targeting ezrin and a scrambled siRNA were obtained as a pool of four or more siRNA duplexes from Dharmacon (Chicago, IL).
Recombinant DNA Constructs
The human wild-type ICAM-1/pAprM8 was kindly provided by Dr. T. A. Springer. To generate the various deletion mutants of ICAM-1, a PCR amplification was performed using human wild-type ICAM-1/pAprM8 as a template and the following primers: a sense primer for all mutants (5'-AGGATCC1ATGGCTCCCAGCAGC15-3') containing the BamHI restriction site and an antisense primer for IC1
CTD (5'-AGCGGCCGC1512GTTATAGAGGTACGTGCT-G1494-3'), IC1
509-532 (5'-AGCGGCCGC1524CTTCCGCTGGCGGTTATAG1506-3'), IC1
517-532 (5'-AGCGGCCGC1548CTGTTGTAGTCTGTATTTCTTG1527-3'), and IC1
521-532 (5'-AGCGGCCGC1560CCCTTTTTGGGCCTGTTGTA-G1540-3') containing the NotI restriction site, respectively. IC1
RKIKK cDNA was generated by an overlapping PCR. In the first PCR reaction, using wild-type ICAM-1/pAprM8 as a template, a 1530-base pair fragment was generated from the sequences of starting codon to the sequences of the 11th codon of the intracellular domain without the internal RKIKK amino acids. Using ICAM-1/pAprM8 as a template, a 94-base pair fragment was also generated. This encodes the last C-terminal amino acids (YNRQYRLQQAQKGTPMKPNTQATPP) of ICAM-1 followed by a stop codon and a NotI site. In the final PCR reaction, the 1530- and 94-base pair products were used together as an overlapping template to generate an IC1
PKIKK. The PCR products were then subcloned as BamHI/NotI fragments into a pEF1/V5-His-puro (Invitrogen) vector in which the neomycin-resistant gene was replaced by puromycin.
ICAM-1/pEGFP-N1 was obtained using the corresponding ICAM-1/pEF1/V5-His-puro as templates by PCR amplification of the complete or partial encoding region of the molecule without the stop codon. A HindIII site was added to the 5' end and a SacII site at the end of wt-IC1 and IC1
RKIKK cDNAs. Likewise, NheI and HindIII sites were added to the 5' and 3' ends of the ICAM-1 mutants. The PCR products were subcloned into pEGFP-N1 (CLONTECH Laboratory, Palo Alto, CA), resulting in an in-frame fusion of enhanced green fluorescent protein (GFP) to the COOH terminus of ICAM-1. The amino acid sequences of a linker polypeptide between wt-IC1 or IC1
RKIKK protein and the EGFP residues, were GDPPVAT (7 aa). In the case of C-terminal deletion mutants, we inserted more linker polypeptide in order to adjust a sequence length as in the cytoplasmic domain, thereby overcoming a potential localization problem. The amino acid sequences of a linker polypeptide between mutant ICAM-1s and EGFP, were KLRILQSTVDRARDPPVAT (19 aa).
To generate wild-type ezrin (wt-ezrin) construct, human ezrin clone coding for the full-length open reading frame of ezrin was purchased from RZPD German Resource Center (Berlin, Germany). Wt-ezrin cDNA was then transferred into the pcDNA3 vector (Invitrogen) using EcoRI and XhoI restriction sites. Wt-ezrin_RFP was generated using PCR amplification from wt-ezrin/pcDNA3, and subcloned into the pDsRed1-N1, thereby resulting in an in-frame fusion of RFP to the COOH terminus of wt-ezrin. DN-ezrin1320/pEGFP-N1 was a generous gift from Dr. Stephenie M. Takahashi (National Institutes of Health, Bethesda, MD). DN-ezrin1320 was transferred into pDsRed1-N1 vector (CLONTECH Laboratory) to produce DN-ezrin_RFP construct.
PECAM-1/pcDNA3 was kindly provided by Dr. Peter J. Newman (Blood Research Institute, Milwaukee, WI). To generate PECAM-1 fused to GFP at its C terminus, the stop codon of PECAM-1 was replaced with an EcoRI restriction site through the PCR amplification of the entire coding region of PECAM-1. The resultant PCR product was digested with HindIII and EcoRI and subcloned into the pEGFP-N1 vector (CLONTECH Laboratory), thus giving rise to the plasmid PECAM-1/pEGFP-N1.
Cell Transfection and Establishment of Stable Cell Lines
COS-7 cells were transiently transfected with cDNAs encoding wild-type or mutant ICAM-1s using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. In some experiments, COS-7 cells were transiently cotransfected with ICAM-1 and wt-ezrin_RFP or DN-ezrin_RFP and then used for the localization studies at 2448 h after transfection.
For siRNA transfections, COS-7 cells were treated for 48 h with 1 µg of siRNA targeting ezrin or a scrambled siRNA premixed with DharmaFECT 2 according to the manufacturer's instructions. The cells were then retransfected with wt-ICAM-1_GFP for 24 h and the effect of siRNA on the expression of ezrin was examined by immunofluorescence staining analysis.
Stable COS-7 transfectants were established using the Lipofectamine 2000 reagent (Invitrogen) transfection of ICAM-1/pEGFP-N1 or ICAM-1/pEF1 V5 His-puro, followed by selection with 1 mg/ml geneticin or 3 µg/ml puromycin (Invitrogen, Gaithersburg, MD), respectively. The cells were then subjected to a fluorescence-activated cell sorter (FACS) and were sorted in order to obtain ICAM-1positive cells selectively; they were then cultured in complete medium supplemented with the same concentrations of antibiotics.
HUVECs were transiently transfected with cDNAs encoding wild-type or mutant ICAM-1s using a Nucleofector device and corresponding kits (Amaxa, Cologne, Germany). HUVECs were harvested at days 3 or 4 of culture, washed once in cold phosphate-buffered saline, and resuspended in the specified electroporation buffer to a final concentration of 2.5 x 105 cells/0.1 ml. Two micrograms of plasmid DNA was mixed with 0.1 ml of cell suspension, transferred to a 2.0-mm electroporation cuvette, and nucleofected with an Amaxa Nucleofector apparatus (Amaxa, Cologne, Germany) according to the manufacturer's instructions. After electroporation, cells were immediately transferred to 5.0 ml of complete medium and cultured in six-well plates at 37°C until analysis.
Penetratin-ICAM-1 Peptides
Penetratin peptides were N-terminally biotinylated and consisted of 16 residues of the penetratin sequence (RQIKIWFQNRRMKWKK) as previously described (Greenwood et al., 2003
). The 14 C-terminal or 507RKIKK511 amino acids of human ICAM-1 were synthesized distal to the penetratin sequence. The sequences used for ICAM-1 were RQRKIKKYRLQQAQ, RKIKK, and an irrelevant sequence was from the soluble part of rat rod opsin (CKPMSNFRFGENH). Peptides were HPLC-purified before use. Localization of penetratin peptides was detected in cells using streptavidin-Texas red after fixation in 3.7% formaldehyde and permeabilization with 0.2% Triton X-100.
Immunofluorescence Staining and Confocal Imaging Analysis
Cells (COS-7 transfectants or HUVECs) were grown on glass coverslips (18-mm diameter; Fisher Scientific, Pittsburgh, PA) or on chamber slides (Nalge Nunc International, Naperville, IL). HUVECs were treated for various times (012 h) with TNF-
(10 ng/ml). The cells were fixed, washed twice with PBS, and blocked with 5% goat serum (DAKO, Glostrup, Denmark) in PBS for 30 min. The cells were then incubated with primary antibodies in blocking buffer for 3 h at RT, rinsed three times with PBS, incubated with secondary antibody in blocking buffer for 1 h at RT, rinsed three times with PBS, and mounted with anti-fade solution (Molecular Probes). The primary antibodies used were anti-ICAM-1 (R6.5), anti-ezrin, anti-moesin, and anti-pERM; the secondary antibodies used were Cy5-conjugated goat anti-mouse and anti-rabbit IgG (Molecular Probes). F-actin was detected using Phalloidin-TRITC (Sigma). To stain the ERM protein family, cells were permeabilized for 5 min with PBS containing 0.1% Triton X-100 at RT before incubation with primary antibody. The slides were examined with an FV1000 confocal laser scanning microscope (Olympus, Tokyo, Japan) equipped with 40x, 63x, and 100x objectives.
For the colocalization analysis, the Z section cutting area through the apical surface was chosen. Images captured at different wavelengths were superimposed, and the intensity of expression for each fluorochrome in the field was then plotted in a scattergram by FLUOVIEW software (Olympus). Overlapping degree of intensity (ODI) value was calculated by FLUOVIEW software. Colocalization percentage was then derived from the ODI, multiplying by 100.
For measuring microvilli length, images captured were traced using the free line tool bar on FLUOVIEW software and were analyzed by measurement analysis. Microvilli in 810 cells were calculated for the measurement of microvilli length.
Flow Cytometric Analysis
Single-cell suspensions obtained after EDTA (5 mM/PBS) treatment were collected by centrifugation and were washed once in PBS containing 1% bovine serum albumin (BSA). The cells were resuspended in 1% BSA/PBS for 30 min on ice. For extracellular staining, the cells were then incubated with ICAM-1 antibody (R6.5) for 1 h on ice, washed once with 1% BSA/PBS, and incubated with PE or FITC-conjugated anti-mouse IgG for 1 h on ice. After two further washes with 1% BSA/PBS, samples were analyzed and quantified using the FACScan cell analyzer (Becton Dickinson, San Jose, CA). Appropriate isotype-matched Ab controls were used in each experiment. Cells for sorting were incubated as described above and were then sorted on an FACSAria (Becton Dickinson, San Jose, CA) machine equipped with a 5-W argon and a 30-mW helium neon laser. Sorted cells were collected into sterile Eppendorf vials in complete medium.
Immunoprecipitation and Western Blotting
Cells (COS-7 transfectants) were lysed in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, containing 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.1% deoxycholate, 5 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM 4-nitrophenyl phosphate, 10 µg/ml leupeptin, 10 µg/ml pepstatin A, and 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride) for 1 h on ice. Cell lysates were centrifuged at 15,000 rpm for 20 min at 4°C, and the supernatant was incubated with R6.5-bead conjugates at 4°C overnight with rotation. Immune complexes were then washed in lysis buffer, eluted with SDS sample buffer (100 mM Tri-HCl, pH 6.8, 4% SDS, 20% glycerol with bromophenol blue), and heated for 5 min. The proteins were separated through 810% SDS-PAGE gels and were transferred into a nylon membrane by means of Trans-Blot SD semidry transfer cell (Bio-Rad, Hercules, CA). The membrane was blocked in 5% skim milk (1 h), rinsed, and incubated with intended antibodies (anti-GFP, anti-ezrin, and anti-ICAM-1 antibodies) in TBS containing 0.1% Tween 20 (TBS-T) and 3% skim milk for 2 h. Excess primary antibody was then removed by washing the membrane four times in TBS-T. The membrane was then incubated with 0.1 µg/ml peroxidase-labeled secondary antibody (against rabbit or mouse) for 1 h. After three washes in TBS-T, bands were visualized by ECL Western Blotting Detection reagents and were then exposed to x-ray film.
Live-Cell, Time-Lapse Confocal, and EPI Fluorescence Imaging
For live-cell time-lapse confocal imaging, COS-7 cells expressing wt-IC1, IC1
CTD, or IC1
RKIKK (with or without GFP form) were seeded at 2 x 105 on 18-mm glass coverslips. After overnight culture, the coverslips were mounted in a chamber device. In some experiments, PBLs (1 x 106 cells/coverslip) were added on the COS-7 cells (Supplementary Figure S4B and Figure 7). PBLs were allowed to settle for 10 min at 37°C and were then activated by adding CBR-LFA-1/2 antibody. During the live-cell imaging, chamber devices were maintained at 37°C in a 5% CO2 atmosphere using a live-cell instrument system (Live Cell Instrument, Inc., Seoul, Korea). Confocal series of fluorescence and differential interference contrast (DIC) images were simultaneously obtained at 20-s intervals using an 63x oil immersion objective on FV1000 confocal microscope (Olympus). The images were processed and assembled into movies using Olympus FLUOVIEW software ver.1.5.
For EPI fluorescence imaging, cells transfected with wt-IC1_GFP were prepared as described above. Live-time EPI fluorescence and DIC images were taken at 30-s intervals with a 40x objective in an Axiovert 200 fluorescence microscope (Carl Zeiss, Jena, Germany). Images were analyzed using Axiovision software ver. 3.1 (Zeiss).
Scanning Electron Microscopy
COS-7 cells expressing WT-IC1 or IC1
CTD in pEF1/V5-His-puro were analyzed by scanning electron microscopy (Model S-4800, Hitachi, Tokyo, Japan). The cells were seeded on 18-mm glass coverslips. After overnight culture, the coverslips were fixed in a solution of 4% formaldehyde and 2% glutaraldehyde in PBS overnight at 4°C. The cells were then washed twice with 0.1 M cacodylate buffer, dehydrated in graded ethanol, and air-dried at room temperature. The cells on coverslips were mounted on SEM stubs with double-sided carbon tape, and were then coated gold-palladium in a vacuum evaporator. The cells were observed and photographed with SEM operated at 10 kV.
Understatic Adhesion and Transmigration Assays
For cellular adhesion assays, stable COS-7 cells (1 x 105 cells/well) or HUVECs (5 x 104 cells/well) were grown to confluence in 96-microwell plates (Costar, Pittsburgh, PA). HUVECs were stimulated for 12 h with TNF-
(10 ng/ml) and were then treated for 2 h with penetratin-ICAM-1s (100 µg/ml) before use. PBLs (2 x 105 cells/200 µl) were labeled with 1 µM of BCECF-AM for 15 min at 37°C, preincubated with CBR-LFA-1/2 antibody (for adhesion assay on COS-7 cells only), and allowed to adhere to the bottom cells in Lefkovitz L15 media supplemented with 5% FBS (L15/5% FBS) for 30 min at 37°C. Unbound PBLs were then removed and the fluorescence intensity was measured in a microplate reader (FL500, Biotek, Winooski, VT).
PBL migration through a confluent monolayer of stable COS-7 transfectants or TNF-
stimulated HUVECs was assayed in 3-µm pore Transwell cell culture chambers (Costar). Stable COS-7 transfectants (1 x 105 cells/well) expressing wild-type or mutant ICAM-1s or HUVECs (1 x 105 cells/well) were seeded and grown to confluence on these Transwell inserts. HUVECs were further treated with TNF-
and penetratin-ICAM-1s as described above. In the low chamber, 600 µl of complete medium with or without 100 ng/ml human SDF-1
, were poured before PBL was added into the upper chamber. Cells were incubated for 3 h at 37°C, and migrated cells were recovered from the lower chamber. The relative number of migrated cells was estimated by flow cytometry.
Underflow Adhesion and Migration Assays
Stable COS-7 transfectants (2 x 105) were seeded on 22-mm glass coverslips, grown to confluence, and then preincubated with SDF-1
(100 ng/ml) for 10 min. Coverslips were mounted in a flow chamber device and maintained at 37°C in a 5% CO2 atmosphere as described on live-cell time-lapse imaging. For underflow adhesion and detachment assays, PBLs were resuspended at 2 x 106/ml in L15/5% FBS, loaded into the chamber under shear stress at 0.2 dyn/cm2 for 5 min, and then subjected to a constant shear force of 4 dyn/cm2 for 15 min. In some experiments, the shear force was increased up to 20 dyn/cm2 for 10 min after the initial shear force of 0.2 dyn/cm2 for 5 min and 4 dyn/cm2 for 5 min. The number of cells attached after shear stress was quantified by a direct visualization of six to eight different fields (40x oil immersion objective). For underflow migration assay, the behaviors of PBLs on the monolayers of COS-7 transfectants at 4 dyn/cm2 were monitored on confocal microscopy by obtaining DIC images at 20-s intervals (40x60x oil immersion objective). Images were analyzed using Olympus FLUOVIEW software ver. 1.5.
HUVECs (2 x 105) were also seeded on 22-mm glass coverslips, grown to confluence, and then pretreated with TNF-
(10 ng/ml) for 12 h. The cells were further incubated with penetratin-ICAM-1 peptides for 2 h and washed three times with serum-free medium (EGM). To visualize ICAM-1 on plasma membrane, HUVECs were then treated with Cy3-conjugated anti-ICAM-1 Fab (CBR-IC1/11-Fab-Cy3) for 10 min after treatment with SDF-1
(100 ng/ml). The PBL adhesion and migration assays were performed as described in COS-7 transfectants. Confocal series of fluorescence and DIC images were simultaneously obtained at 20-s intervals with 40x63x oil immersion objective lens in an FV1000 confocal microscope, and images were analyzed as described above. The PBLs that remained firmly adherent were scored for adhesion. The PBLs that randomly migrated on the monolayers of endothelial cells were scored for migration. The PBLs that underwent shape changes to flattened morphology together with the redistribution of ICAM-1 on HUVECs were scored for transmigration. The number of adhered, migrated, and transmigrated PBLs was counted by a direct visualization of six to eight randomly selected fields (40x oil immersion objective), respectively, and the total number of cells in each field was considered as 100%. The results are expressed as the percent adhesion, migration (lateral), and transmigration of binding PBLs in each field.
Online Supplementary Material
Supplementary Figure S1 shows the localization of wild-type ICAM-1 or ICAM-1 mutant lacking an intracellular domain on the surface of primary HUVECs. Supplementary Figure S2 shows that pERM is localized on the tip of growing microvilli in COS-7 cells expressing wt-IC1_GFP. Supplementary Figure S3 shows that activation of HUVECs by TNF-
induces ICAM-1 and microvillar elongation. Supplementary Figure S4 shows the dynamic movement of ICAM-1 clusters on the surface of COS-7 wt-IC1_GFP cells. Supplementary Videos 1 and 2 (corresponding to Figure 1, C and D, respectively) show a microvillus redistribution of wt-IC1_GFP or ICl
CTD_GFP at the marginal zone of cells. Supplementary Video 3 (corresponding to Supplementary Figure S4A) shows a continuous and directional movement of wt-IC1_GFP clusters on the cell surface by EPI fluorescence. Supplementary Video 4 (corresponding to Supplementary Figure S4B) shows a clustering of wt-IC1_GFP in the interface between PBLs and COS-7 cells. Supplementary Video 5 (corresponding to Figure 7A) shows a 3D view of ICAM-1mediated membrane projection upon binding to LFA-1 on leukocytes. Supplementary Videos 6 and 7 (corresponding to Figure 7B) show membrane projections mediated by wt-IC1_GFP (Supplementary Video 6) and IC1
RKIKK_GFP (Supplementary Video 7). Supplementary Videos 8 and 9 (corresponding to Figure 8) show leukocyte binding to and migration on monolayers of COS-7 cells that express wt-IC1 (Supplementary Video 8) or IC1
RKIKK (Supplementary Video 9) in a parallel wall flow chamber. Supplementary Videos 10 and 11 (corresponding to Figure 10C) show leukocyte binding to and migration through the monolayers of TNF-
/SDF-1
activated HUVECs that were pretreated with penetratin-ICAM-1s.
| RESULTS |
|---|
|
|
|---|
CTD_GFP) in order to investigate potential function of intracellular domain on the distribution and localization of ICAM-1. Although earlier studies have utilized the CHO cell system to overcome the problem of multiple adhesion receptors found on endothelial cells (Sans et al., 2001
We first examined the cell surface distribution of the two forms of ICAM-1 using confocal microscopy and flow cytometry. Wt-IC1_GFP was most prominent of the microvillar projections on the membrane surface, and this was strongly colocalized with the signals detected by the anti-ICAM-1 antibody (R6.5; Figure 1A, left). The majority of IC1
CTD_GFP, on the other hand, was uniformly distributed on the cell membrane (Figure 1A, left). Because both proteins were well expressed on the cell surface, as evidenced by the surface staining of the anti-ICAM-1 antibody in flow cytometric analysis (Figure 1B), uniform distribution of IC1
CTD_GFP may not result from improper expression. To rule out the possibility that the fusion of ICAM-1 with GFP by itself alters the distribution of ICAM-1 on the cell surface, COS-7 cells were also transfected with ICAM-1 constructs without GFP and were stained with anti-ICAM-1 antibody. No significant difference was detected between the cells that express ICAM-1 with and without GFP (Figure 1A, right), thereby suggesting that GFP has little effect on the expression and distribution of ICAM-1 on the cell surface. Time-lapse microscopic analysis revealed that wt-IC1_GFP is condensed to the newly formed microspikes at the marginal zone of the cells, whereas IC1
CTD_GFP barely shows condensed distribution (Figure 1, C and D; see Supplementary Videos 1 and 2). To further test whether the results from COS-7 were applicable to the endothelial cells, we examined the cell surface distribution of the wt-IC1_GFP and IC1
CTD_GFP on HUVECs. As shown in Supplementary Figure S1, the physical distributions of two forms of ICAM-1 on HUVECs were similar to that of COS-7 cells.
|
CTD_GFP. Wild-type ICAM-1 colocalized with F-actin, ezrin, and moesin in the microspikes and microvilli that protrude from the apical surface of these cells (Figure 2, AC). Colocalization scattergram analysis also confirmed these observations (Figure 2, AC). In contrast, ICAM-1 lacking an intracellular domain revealed reduced colocalization with F-actin and with the ERM family (Figure 2, AC). Taken together, these results demonstrate that the intracellular domain is critical for the proper localization of ICAM-1 on the microvilli, presumably by its interaction with F-actin and ERM proteins.
|
CTD_GFP-transfected cells (Figure 3B). Interestingly, the phospho-type of ERMs (pERM) was mostly localized on the tip of growing microvilli in COS-7 wt-IC1_GFP (Supplementary Figure S2). This result may suggest that microvillar protrusion is initiated on the apical side of microvilli. Similar results were also observed when HUVECs were treated with TNF-
(10 ng/ml; Supplementary Figure S3, A and B). In these cells, the microvillar elongation was also highly dependent on the expression levels of ICAM-1, as determined by confocal microscopic imaging (Supplementary Figure S3, A and B) and by flow cytometric analysis (Supplementary Figure S3C).
|
CTD localization (Figure 4A). We secondarily examined the effect of siRNA targeted to the ezrin. As shown in Figure 4B, transfection with the siRNA targeting the ezrin significantly reduced the endogenous ezrin expression. Accordingly, it also inhibited ICAM-1induced microvilli formation in COS-7 cells. Taken together, these results strongly suggest that normal functioning of ezrin is required for the ICAM-1induced microvillar elongation. To further test whether the microvillar elongation is also mediated by other endothelial membrane proteins, we examined the effect of PECAM-1 (CD31). Transfection of COS-7 cells with the cDNA encoding PECAM-1 (either wild type or GFP-fused form) did not induce the microvilli formation, but rather most cells revealed a uniform distribution of PECAM-1 on the cell surface (Figure 4C).
|
521-532_GFP and IC1
517-532_GFP. Second, as 507RKIKK511 of five amino acids in the NH-terminal third of the intracellular domain has been known as an
-actininbinding motif (Carpen et al., 1992
RKIKK_GFP) or part (IC1
509-532_GFP) of the 507RKIKK511 residues. All of the mutant ICAM-1s were properly folded and were well expressed on the cell surface, as determined by immunoprecipitation and flow cytometric analysis (Figure 5B, right). Interestingly, however, there were significant differences of their physical distributions on the cell surface. As shown in Figure 5B in the left panel, deletion of the C-terminal 16 amino acids (IC1
517-532_GFP) showed no significant effect on the expression and localization of ICAM-1 on the microvilli compared with wild-type ICAM-1. In contrast, deletion of all (
RKIKK) or the C-terminal 24 amino acids, including 509IKK511 residues (
509-532), revealed uniform distribution of ICAM-1 on the cell surface. Moreover, both constructs (IC1
RKIKK_GFP and IC1
509-532_GFP) failed to induce F-actin formation, which represented a weak association with F-actin (Figure 5C). In addition, deletion of the 507RKIKK511 residues revealed reduced colocalization with ezrin and moesin (data not shown).
|
CTD, and IC1
RKIKK were transfected with cDNA containing wt-ezrin. As shown in Figure 6, wt-IC1 was coimmunoprecipitated with ezrin, whereas both IC1
CTD and IC1
RKIKK were not coimmunoprecipitated with ezrin. Taken together, these results strongly suggest that RKIKK is a critical motif for the interaction of ICAM-1 with the ERM proteins.
|
25 min), although this was not observed in IC1
RKIKK_GFP-expressing cells (data not shown). In addition, upon binding to LFA-1 on leukocytes, these clusters were rapidly redistributed and formed a ringlike cluster at the leukocyteendothelial junctional interface (Supplementary Figure S4B; see Supplementary Video 4). As ICAM-1 clusters in microvilli are not static but are actively moving on the cell surface, it also suggests the importance of the intracellular domain in the spatial and physical dynamics of ICAM-1.
Recently, as shown in Figure 7A (see also Supplementary Video 5), several reports have demonstrated that ICAM-1 and activated moesin and ezrin are rapidly clustered in an endothelial actin-rich docking structure during leukocyte adhesion onto endothelial cells (Barreiro et al., 2002
; Carman et al., 2003
; Carman and Springer, 2004
). We found that the ability of each construct to support leukocyte adhesion in the presence of CBR-LFA-1/2 mAb (activation antibody) was similar to that of wild-type ICAM-1, as measured by under static adhesion assay (see Figure 8A). Nevertheless, the velocity to form a ring-shaped membrane projection in response to binding to LFA-1 on human PBLs, was significantly more retarded in cells expressing mutant ICAM-1s lacking the RKIKK motif (IC1
CTD_GFP, IC1
RKIKK_GFP, and IC1
509-532_GFP) than in cells expressing wild-type ICAM-1 (wt-IC1_GFP) or mutant ICAM-1s with the RKIKK motif (IC1
521-532_GFP and IC1
517-532_GFP), as measured by time-lapse confocal microscopy (Figure 7B; see Supplementary Videos 6 and 7). As a consequence, the number of ring-shaped projections per cell was also reduced in cells expressing mutant ICAM-1s lacking the RKIKK motif (Figure 7C). Overall, compared with the cells expressing ICAM-1s with the RKIKK motif, the percent of ring-shaped projection formed by binding with the LFA-1bearing cells was significantly diminished in the cells expressing ICAM-1 lacking the RKIKK motif (Figure 7D).
|
|
CTD, IC1
RKIKK, and IC1
509-532 in response to chemokine SDF-1
was significantly reduced compared with that of COS-7 wt-IC1 (Figure 8B).
To more preciously evaluate whether the results from the above static adhesion assay are applicable to the physiological shear flow condition, we characterized PBL binding to and migration on monolayers of COS-7 cells that express wt-IC1 or IC1
RKIKK in a parallel wall-flow chamber. For this experiment, we used ICAM-1 constructs without GFP to reduce a potential effect of the GFP protein. PBLs were accumulated on SDF-1
pretreated mono-layers of COS-7 wt-IC1 or COS-7 IC1
RKIKK mounted on the bottom wall of the flow chamber for 5 min at 0.2 dyn/cm2 and then subjected to a constant shear force of 4 dyn/cm2 for 15 min. To further test whether PBL binding on COS-7 expressing ICAM-1 mutants is also resistant to detachment under increasing shear stress, the shear force was increased up to 20 dyn/cm2 (10-fold more than physiological shear stress) for 10 min after the initial shear force at 0.2 dyn/cm2 for 5 min and 4 dyn/cm2 for 5 min. The initial binding of leukocytes to the monolayers of COS-7 IC1
RKIKK was not significantly different from that of COS-7 wt-IC1 in terms of the number of bindings per cell under shear force at 0.2 dyn/cm2 (data not shown). In addition, little change of leukocyte adhesion was observed under shear force at 4 dyn/cm2 (Figure 9A). Interestingly, however, there was a slight but significant reduction of leukocyte adhesion on the monolayers of COS-7 IC1
CTD, IC1
RKIKK, and IC1
509-532 under shear force at 20 dyn/cm2 (Figure 9A), thereby suggesting that spatial and physical distribution of ICAM-1 on the cell surface may also affect the avidity of ICAM-1. In addition, most leukocytes that adhered to the COS-7 wt-IC1 underwent shape changes to more flattened morphology and migrated rapidly on or across monolayers during the incubation period. In contrast, leukocytes on COS-7 IC1
RKIKK cells remained as round in shape and revealed reduced motilities (Figure 9B; see Supplementary Videos 8 and 9). Taken together, these results strongly suggest that ICAM-1 topography on the cell surface has an important functional consequence in leukocyte-adhesioninduced morphological changes, migration, and transmigration.
|
activated HUVECs. Thus, treatment with either the P-CTD or P-RKIKK resulted in adhesion values 101.2 ± 4 (n = 4) and 98.3 ± 6% (n = 4) of control (TNF-
alone) values, respectively. Interestingly, however, P-CTD and P-RKIKK were both effective in attenuating TEM of leukocytes through monolayers of HUVECs. Both P-CTD and P-RKIKK peptides reduced TEM to 44.2 ± 3 and 51.2 ± 3% of the control value (p < 0.05; n = 4), respectively (Figure 10A).
|
(10 ng/ml) for 12 h and then treated with penetratin-ICAM-1 peptides for 2 h. To visualize the dynamic distribution of ICAM-1 on endothelial cells, cells were further stained for 10 min with Cy-3conjugated anti-ICAM-1-Fab (CBR-IC1/11-Fab-Cy3). HUVECs were washed at least three times with serum-free medium to minimize abnormal clustering of penetratin peptide with antibody at the plasma membrane of cells. In all experiments, HUVECs were incubated with SDF-1 before use (
30 min). We found that P-CTD or P-RKIKK has little effect on the ICAM-1 distribution (Figure 10B) as well as viability (data not shown). Using live-cell time-lapse imaging, we then carefully monitored the behaviors of leukocytes on the HUVECs that were pretreated with penetratin-ICAM-1 peptides. The initial binding of leukocytes was not significantly altered by the treatment with the penetratin-ICAM-1 peptides (data not shown). In control (TNF-
/SDF-1) or irrelevant peptide-treated cells, most leukocytes underwent shape changes to flattened morphology in response to binding on HUVECs during the measuring time (see Supplementary Video 10). Interestingly, in parallel with the shape changes of leukocytes, there were also dynamic redistributions of ICAM-1 on the HUVECs, implying a trans- or para-cellular leukocyte migration (Supplementary Video 10; Carman and Springer, 2004| DISCUSSION |
|---|
|
|
|---|
-actininbinding motif, in the intracellular domain is required for 1) localization of ICAM-1 on the microvilli; 2) association with F-actin, ezrin, and moesin; 3) redistribution of ICAM-1 in a newly formed ring-shaped membrane projection upon binding to LFA-1bearing leukocytes; 4) supporting adhesion and migration of leukocytes under shear force; and eventually 5) leukocyte TEM. The functional role of RKIKK motif of ICAM-1 was further proved in the endothelial cells, by testing the effects of the penetratin-ICAM-1 peptides.
ICAM-1 appears to exist as a dimer or higher multimers in its native state on the cell surface, as shown by cross-linking studies (Miller et al., 1995
; Reilly et al., 1995
), and it has been postulated that the multimeric form of ICAM-1 mediates better adhesion to LFA-1. However, the relative importance of the topographical distribution of ICAM-1 in connecting with its function to mediate leukocyte transmigration has been less extensively investigated. Our current results using time-lapse EPI microscopy unambiguously represent that ICAM-1 clusters are not just staying in one place but are moving continuously on the entire membrane surface of cells. On engagement with LFA-1 on leukocytes, these clusters are rapidly joined at the junctional interface of leukocyte/endothelial interactions. As mutant ICAM-1 lacking an intracellular domain did not show any of these features, these results strongly suggest that an intracellular domain is vital for the proper positioning of ICAM-1 on the microvilli through which ICAM-1 may play a pivotal role for leukocyte migration.
It is interesting to note that the expression levels of ICAM-1 correlated with the elongation of microvilli as determined by flow cytometric analysis, confocal microscopy, and scanning electron microscopy. These results suggest that the intracellular domain has an essential motif that is not just for associating with actin but for actively functioning as an organizer for the recruitment of actin filaments, thereby inducing microvillar elongation. In this regard, the question has naturally arisen which site(s) in the intracellular domain is(are) responsible for this event. Our results strongly indicated that the 507RKIKK511 residues, which were previously identified as an
-actininbinding motif (Carpen et al., 1992
), play a pivotal role for the microvillar organization and ICAM-1 association with F-actin, ezrin, and moesin. In mutagenesis analysis, deletion of all (
RKIKK) or part (
509-532) of the 507RKIKK511 residues significantly diminishes ICAM-1dependent microvillar elongation, whereas deletion (
517-532 or
521-532) of the C-terminal remaining amino acids except for 507RKIKK511 has no significant effect. A striking feature of 507RKIKK511 residues is the presence of positively charged amino acids. A positively charged amino acid cluster in the juxta-membrane portion has been identified as an ERM protein-binding region in CD43, CD44, and ICAM-2 (Legg and Isacke, 1998
; Yonemura et al., 1998
). Therefore, instead of binding to
-actinin, this motif may also serve as a binding site for ERM proteins. Importantly, we found that RKIKK is a critical motif for the binding of ezrin, as determined by immunoprecipitation.
The important questions raised at this point are as follows: 1) What is a functional consequence of ICAM-1 localization on the microvilli? 2) Does microvillar elongation by ICAM-1 have any effect on leukocyte transmigration? and if so 3) What is the primary mechanism by which the spatial and physical distribution of ICAM-1 affects leukocyte transmigration across the endothelial cells? During leukocyte adhesion onto endothelial cells, ICAM-1 is rapidly relocalized to the newly formed membrane projection that is later known as a functionally important architecture for the para- and transcellular migration of leukocytes (Barreiro et al., 2002
; Carman et al., 2003
; Carman and Springer, 2004
). Of particular importance, in the present results (Figure 7), dramatic reduction of membrane projection in mutant ICAM-1 lacking RKIKK strongly demonstrates that RKIKK is a critical motif for the ICAM-1 in connecting intracellular domain to the cytoskeletons and signaling networks. In agreement with this observation, a previous report demonstrated that membrane projections require intact microfilaments, microtubules, and calcium signaling (Carman et al., 2003
). To better understand the role of the microvillus presentation of ICAM-1 in physiological condition, we measured the leukocyte adhesion and migration under shear flow. Interestingly, leukocytes that adhered onto COS-7 wt-IC1 underwent dramatic shape changes and represented a flattened morphology. This shape change may help leukocytes to migrate on or across monolayers of endothelial cells under shear stress although the detailed mechanism is not determined in our present study. Because it has been demonstrated that rapidly migrating T lymphocytes form clustering of LFA-1 called "focal zone" in the midcell zone (Smith et al., 2005
), it could be possible that the microvillus presentation of ICAM-1 may facilitate focal zone induction, thereby supporting leukocyte migration under shear stress. The shape change became noticeably more prominent when the leukocytes were loaded on the TNF-
activated primary endothelial